AU2017274416C1 - Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders - Google Patents

Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders Download PDF

Info

Publication number
AU2017274416C1
AU2017274416C1 AU2017274416A AU2017274416A AU2017274416C1 AU 2017274416 C1 AU2017274416 C1 AU 2017274416C1 AU 2017274416 A AU2017274416 A AU 2017274416A AU 2017274416 A AU2017274416 A AU 2017274416A AU 2017274416 C1 AU2017274416 C1 AU 2017274416C1
Authority
AU
Australia
Prior art keywords
fecal
pharmaceutical composition
composition
group
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017274416A
Other languages
English (en)
Other versions
AU2017274416A1 (en
AU2017274416B2 (en
Inventor
Thomas J. Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finch Therapeutics Holdings LLC
Original Assignee
Finch Therapeutics Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finch Therapeutics Holdings LLC filed Critical Finch Therapeutics Holdings LLC
Publication of AU2017274416A1 publication Critical patent/AU2017274416A1/en
Application granted granted Critical
Publication of AU2017274416B2 publication Critical patent/AU2017274416B2/en
Assigned to FINCH THERAPEUTICS HOLDINGS LLC reassignment FINCH THERAPEUTICS HOLDINGS LLC Amend patent request/document other than specification (104) Assignors: CRESTOVO HOLDINGS LLC
Publication of AU2017274416C1 publication Critical patent/AU2017274416C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017274416A 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders Active AU2017274416C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344053P 2016-06-01 2016-06-01
US62/344,053 2016-06-01
PCT/US2017/035449 WO2017210428A1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders

Publications (3)

Publication Number Publication Date
AU2017274416A1 AU2017274416A1 (en) 2019-01-03
AU2017274416B2 AU2017274416B2 (en) 2022-01-27
AU2017274416C1 true AU2017274416C1 (en) 2022-07-07

Family

ID=60479147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017274416A Active AU2017274416C1 (en) 2016-06-01 2017-06-01 Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders

Country Status (7)

Country Link
US (2) US20170348360A1 (https=)
EP (1) EP3462882A4 (https=)
JP (1) JP2019520340A (https=)
CN (1) CN109803534A (https=)
AU (1) AU2017274416C1 (https=)
CA (1) CA3026414A1 (https=)
WO (1) WO2017210428A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102534545B1 (ko) 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
MY201921A (en) * 2017-06-16 2024-03-23 Biofermin Pharmaceutical Co Ltd Agent for preventing or treating fat-associated diseases and/or inflammation
WO2018236979A1 (en) * 2017-06-20 2018-12-27 Cornell University Probiotic compositions and methods
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
EP3725321A4 (en) * 2017-12-12 2021-09-08 Morinaga Milk Industry Co., Ltd. COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
GB2585291B (en) * 2018-02-02 2023-07-19 Univ Hong Kong Chinese Fecal fungome and therapeutic efficacy of fecal microbiota transplantation
WO2019157566A1 (en) * 2018-02-16 2019-08-22 St Vincent's Hospital (Melbourne) Limited Compositions and methods for promoting gut health
AU2019253616A1 (en) * 2018-04-13 2020-11-05 Med-Life Discoveries Lp Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof
CN110396538B (zh) * 2018-04-24 2023-05-23 深圳华大生命科学研究院 偏头痛生物标志物及其用途
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12144834B2 (en) * 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
EP3856212A1 (en) 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
US20220218761A1 (en) * 2019-05-06 2022-07-14 The General Hospital Corporation Monitoring and altering the gut microbiome in disease
US11766464B2 (en) 2019-07-11 2023-09-26 Antony MILIS Method for gut mucosa preparation to enhance microbial engraftment
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
EP4045069A1 (en) * 2019-10-18 2022-08-24 Thaena Inc. Fecal-derived sterile postbiotic composition and method therefor
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
WO2021163672A1 (en) * 2020-02-14 2021-08-19 Cornell University Transferable microbiota for the treatment of ulcerative colitis
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP3875098A1 (en) * 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
CN115697084A (zh) * 2020-04-01 2023-02-03 沃尔夫森医疗中心 溃疡性结肠炎膳食、配方、产品及其方法
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
EP4188110A4 (en) * 2020-07-30 2024-08-14 Bactana Corp. METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES
CN111888381A (zh) * 2020-09-18 2020-11-06 广西细微生物科技有限责任公司 一种肠道微生物移植工艺
WO2022065957A1 (ko) * 2020-09-28 2022-03-31 주식회사 천랩 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물
JP2024513706A (ja) * 2021-04-01 2024-03-27 メディビーコン，インク． 粘膜治癒をモニタリングする方法
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN113974159B (zh) * 2021-11-02 2023-06-27 美益添生物医药(武汉)有限公司 齿叶乳香树树脂在制备促进肠道有益菌增殖的产品中的应用
CN119183380A (zh) * 2022-05-13 2024-12-24 国立大学法人东京大学 对炎症性肠病(ibd)进行治疗或诊断的方法和组合物
CN115944655A (zh) * 2023-02-14 2023-04-11 上海奇诺普森生物科技有限责任公司 一种肠菌组合物及其在防治自闭症中的应用
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284781A1 (en) * 2014-04-02 2015-10-08 Northwestern University Altered microbiome of chronic pelvic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1510821A1 (en) * 2003-08-27 2005-03-02 Universiteit Utrecht Holding B.V. Diagnosis and treatment of mycobacterial infections
EP3424515A3 (en) * 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
US9968638B2 (en) * 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US20140363397A1 (en) * 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
BR112015009975A2 (pt) * 2012-11-01 2017-07-11 Academisch Ziekenhuis Groningen métodos e composições para a estimulação das bactérias benéficas no trato gastrointestinal
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
BR112015020819A2 (pt) * 2013-03-05 2017-07-18 Academisch Ziekenhuis Groningen uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284781A1 (en) * 2014-04-02 2015-10-08 Northwestern University Altered microbiome of chronic pelvic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEONARD B. WEINSTOCK ET AL: "Small Intestinal Bacterial Overgrowth in Patients with Interstitial Cystitis and Gastrointestinal Symptoms", DIGESTIVE DISEASES AND SCIENCES vol. 53, 12 October 2007, pages 1246-1251 *

Also Published As

Publication number Publication date
CN109803534A (zh) 2019-05-24
JP2019520340A (ja) 2019-07-18
WO2017210428A1 (en) 2017-12-07
US20210106629A1 (en) 2021-04-15
AU2017274416A1 (en) 2019-01-03
CA3026414A1 (en) 2017-12-07
EP3462882A1 (en) 2019-04-10
US20170348360A1 (en) 2017-12-07
AU2017274416B2 (en) 2022-01-27
EP3462882A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
AU2017274416C1 (en) Compositions and methods for treating inflammatory bowel diseases (IBDS) and other disorders
JP7737219B2 (ja) 潰瘍性大腸炎を治療するための方法
US20170360848A1 (en) Methods for treating autism spectrum disorder and associated symptoms
CA3003138A1 (en) Compositions and methods for fecal microbiota-related therapy
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
WO2018071534A1 (en) Compositions and methods for treating irritable bowel syndrome and related disorders
JP2020513018A (ja) パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
US20210260136A1 (en) Compositions and Methods for Treating Multiple Sclerosis and Related Disorders
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
US20200188449A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
US10092601B2 (en) Compositions and methods for treating multiple sclerosis and related disorders
Gupta et al. Synbiotics: promoting gastrointestinal health
WO2021142358A1 (en) Compositions and methods for treating hepatic encephalopathy (he)
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
US11529375B2 (en) Compositions and methods for treating diverticulitis and related disorders
Modesto et al. Effect of probiotic inocula on the population density of lactic acid bacteria and enteric pathogens in the intestine of weaning piglets
HK40009325A (zh) 用於治疗溃疡性结肠炎的方法

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 MAR 2022

HB Alteration of name in register

Owner name: FINCH THERAPEUTICS HOLDINGS LLC

Free format text: FORMER NAME(S): CRESTOVO HOLDINGS LLC

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 MAR 2022

FGA Letters patent sealed or granted (standard patent)